SOMATIC SYSTEMS INCORPORATED (OTC: SMAS)

Detailed Quote: http://www.otcpicks.com/quotes/SMAS.php

Company Profile: http://www.otcpicks.com/somatic-systems/somatic-systems.htm

Somatic Systems is the worldwide center for Clinical Somatics, the groundbreaking drug-free, non-surgical approach to pain relief. This proprietary system uses natural, non-invasive movement techniques - conducted through one-hour hands-on sessions, therapeutic exercises classes, and home exercises lasting as little as 5 minutes a day - to relieve pain and limitation resulting from accident, trauma and repetitive stress, including back pain, knee pain, joint problems, carpal tunnel syndrome, TMJ, scoliosis, bursitis, sciatica, headaches, tendonitis and more. Clinical Somatics also provides performance gains and injury prevention for casual and professional athletes. Somatic Systems is pursuing a 3-part growth strategy, consisting of a nationwide rollout of pain management Somatics Clinics; increased production and distribution of therapeutic videos, books, and other retail self-help Somatics Products; and expanded Somatics Training Programs to supply Clinic practitioners serving medical and orthopedic professionals and institutional and corporate programs. The company operates a suite of web sites offering Somatics information, products, resources and opportunities at www.somatics.org.

SMAS News:

December 2 - Somatic Systems, Inc. Announces Shareholder Conference Date

Somatic Systems, Inc. (OTC: SMAS) will hold its online shareholder conference today, at 4:15 PM Eastern Time. The conference will enable shareholders to communicate directly to the CEO of the company, to get updates and learn more about the company's growth, plans, and activities.

Shareholders can enter the conference at 4:15 PM today via the Somatic Systems' website at http://somatics.org/investors/conference.

The conference occurs on the same day that the national television show "Health Forum" feature on Somatic Systems begins airing. The half-hour television show airs today at 6:30 AM on WRNN-TV in New York, and features Somatic Systems' CEO, faculty, staff, clients and professional students discussing and demonstrating how Somatic Systems' proprietary pain relief methods can help viewers achieve lasting relief from chronic pain, injury, and musculoskeletal disorders without surgery or dependence on medication. The syndicated television program will be rebroadcast four additional times on that network and on as many as 25 other stations throughout the coming year, including national airings on Women's Entertainment (WE tv) and the Travel Channel.

Somatic Systems expects to field calls about this television show and their many other exciting current activities, including their efforts with the US military, auditing and uplisting to the OTCBB, upcoming product developments and nationwide expansion, and additional media appearances on the company's horizon.

Due to the high demand for the conference, the company took questions in advance of the conference, so that as many attendees as possible can get answers to their questions. However, depending on final turnout and the course of conversation, the company expects to be able to take live questions from participants as well.

Shareholders who wish to ask questions are encouraged to visit http://somatics.org/investors/conference today as soon as possible to fill out the "Ask A Question" form if they have not done so already. If new questions arise as time passes before the conference and new company developments occur, Somatic Systems encourages shareholders to submit additional questions.

To make sure there is room for all to attend, even shareholders who just wish to observe the conference should up sign up as soon as possible for the conference at http://somatics.org/investors/conference/signup2008.

"We look forward to an open and meaningful conversation with our shareholders today," stated Somatic Systems CEO Steven Aronstein. "Somatic Systems is undergoing very exciting growth and opportunities, and we want shareholders to be able to learn as much about all of this as possible. We work hard to be available and transparent to shareholders, and we want to take this opportunity for shareholders to get their questions answered and understand the exciting directions we are headed and the shareholder value we are building."

ONCOGENEX PHARMA INCORPORATED (NASDAQ: OGXI) "Up 126.22% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/OGXI.php

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development.

OGXI News:

December 3 - OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

* First-line trial currently shows median overall survival of 27.5 months for OGX-011 in combination with docetaxel and prednisone and a 16.9 months overall survival for docetaxel and prednisone alone.

* Achievement of survival benefit milestone results in release of all remaining escrowed shares of OGXI.

OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved by the FDA based on a survival advantage of 2.4 months over mitoxantrone.

Based on the median overall survival advantage, the Board of Directors of OncoGenex Pharmaceuticals has approved the release of all of the remaining shares held in escrow pursuant to agreements related to Sonus Pharmaceuticals' merger with OncoGenex Technologies described in its Proxy Statement filed with the SEC on July 3, 2008. The escrow agreements provided for the release of 50% of the original number of shares held in escrow following the demonstration of at least a two-month improvement in survival in the OGX-011 arm as compared to the control arm. All milestone shares have now been released from escrow; as of December 3, 2008 there are 5,513,643 shares outstanding.

The trial was conducted and data were analyzed by the National Cancer Institute of Canada, Clinical Trials Group and was supported by a grant from the NCI-Canada with funding from the Canadian Cancer Society. Previous results regarding the primary endpoint analysis (PSA response) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2007.

The study randomized 82 patients with metastatic or locally recurring prostate cancer refractory to hormone therapy. The median survival was 27.5 months for the patients in the OGX-011 arm and 16.9 months for those in the control arm. Results currently indicate that patients in the OGX-011 arm have a death rate approximately 40% lower than patients in the control arm. The current results are based on study data with a median follow-up of approximately 30 months for both arms. Additional survival updates are needed before a mature median survival for the OGX-011 arm can be reported. Based on the current results, OncoGenex has calculated that the final median survival for patients in the OGX-011 arm can not be lower than 22.7 months.

An abstract presenting the mature results is planned to be submitted to the American Society of Clinical Oncology (ASCO) meeting.

LOGICVISION INCORPORATED (NASDAQ: LGVN) "Up 65.31% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/LGVN.php

LogicVision, Inc. provides technology for the design and manufacture of semiconductor devices. It offers a portfolio of products for the automated development, integration, and deployment of embedded test technology, which consists of technology products, design software products, and manufacturing software products. The company's technology products include the embedded test technology that enables customers to design and manufacture the company's embedded test circuit structures. Its design software products comprise a suite of embedded test design software tools for embedded test implementation on application specific integrated circuits and system-on-a-chip (SoC) designs. The company offers manufacturing software products for access and control of embedded test during chip, and system test program development, debug, manufacturing test, and datalogging. Its technology allows semiconductor designers to insert test structures inside semiconductor integrated circuits, and test the functionality and performance of their devices. The company also provides maintenance, design, and technology development contract services. LogicVision licenses its technologies and software products to companies in semiconductor, semiconductor diagnostics, and systems industries. The company serves application specific integrated circuit or SoC designers in systems and fabless companies, and integrated device manufacturers. It sells its products directly, as well as through distributors or independent sales representatives in the United States and internationally. The company was founded in 1992. It was formerly known as LV Software and changed its name to LogicVision, Inc. in 1996. LogicVision is based in San Jose, California.

LGVN News:

December 3 - Virage Logic proposes to acquire LogicVision for $1.05 per share in cash

Virage Logic Corporation (Nasdaq: VIRL) announced that the company sent a proposal late afternoon on December 2nd to the Board of Directors of LogicVision Incorporated (Nasdaq: LGVN) to acquire LogicVision for $1.05 per share in cash. The proposal provides a premium of 114% to LogicVision's closing price of $0.49 on December 1, 2008, and values LogicVision at approximately $10.0 million.

The text of the letter that was sent to LogicVision's Board of Directors follows:

December 2, 2008

Board of Directors LogicVision, Inc.

25 Metro Drive, Third Floor San Jose, CA 95110

Dear Sirs:

We are sincerely disappointed in your unwillingness to engage in any substantive discussions regarding our indication of interest transmitted to you on November 10th regarding an all-cash acquisition of LogicVision, Inc. ("LogicVision") by Virage Logic Corporation ("Virage"). We continue to believe that such a transaction would be to our companies' mutual benefit, and we are unable to understand your refusal to consider a transaction that would appear to be in your stockholders' best interests. We note your response that the company is not for sale, which position we believe deserves serious reconsideration. Your refusal to engage in negotiations regarding a possible sale of the company appears to be premised on unrealistic expectations regarding the future prospects of LogicVision. Recent economic events and the resulting downturn in business spending and the semiconductor market cast serious doubts on LogicVision's long term future as a stand-alone public company.

In response to your apparent unwillingness to engage in negotiations, we are formally making a proposal to acquire all of the outstanding common stock of LogicVision for $1.05 per share in cash, which acquisition would be financed by Virage solely using available cash. This represents a premium of 114% to the closing price for LogicVision's stock as of December 1, 2008. We believe this to be a very fair offer, and if given the opportunity, your stockholders would also agree. We are offering your stockholders an immediate tangible cash return weighed against an uncertain future for LogicVision as a stand-alone public company and all the associated challenges in light of LogicVision's current cash position and foreseeable business prospects.

Benefits for LogicVision Stockholders

We note that LogicVision's previously announced aggressive projections for its current fiscal year appear to be wholly unachievable in light of the downturn in the semiconductor industry and also the rapidly deteriorating macroeconomic environment. In addition, the dramatic decline in LogicVision's stock price during the previous twelve months has meant a 76% decline to your stockholders in the value of their shares during this same period. We believe your stockholders are aware of, and fully appreciate the risks and challenges confronting LogicVision in the current industry and economic environment and will find the cash value we are offering for their shares to be an attractive alternative to the otherwise uncertain future facing LogicVision.

Business Synergies

Virage supplies a broad line of semiconductor IP solutions to the global semiconductor industry and our mission is to serve as the semiconductor industry's trusted IP partner. We have a proven reputation as a highly specialized and efficient developer of semiconductor IP, and today more than 350 customers look to Virage to provide much of the core building blocks of their System-on-Chip designs. We believe an acquisition of LogicVision's business would bring valuable synergies to Virage's existing business and product lines. We also believe that LogicVision's existing customers and business partners would benefit from the more complete and diversified product offerings from our combined companies and from a company with Virage's strong financial position and future.

Process We have invested considerable time and resources in evaluating the prospective benefits and risks of this transaction and are confident that it could be consummated expeditiously in cooperative partnership with your team. Although we have completed preliminary due diligence based on publicly available information, our proposal is of course subject to the completion of customary due diligence, as well as the negotiation of definitive transaction agreements and the satisfaction of necessary approvals and customary conditions to closing of a transaction to be set forth in such agreements. We together with our advisors would be available to meet with you as soon as arrangements can be made to discuss the terms of this proposal and to commence due diligence and the negotiation of definitive documentation for the transaction. Considering the premium we are offering to LogicVision's recent trading price and other compelling benefits of this proposal, we are confident that, given the opportunity, LogicVision's stockholders and customers would be in favor of this offer and the proposed transaction. In light of the foregoing, we ask that you move quickly to engage with us in a meaningful and productive discussion. We look forward to your prompt response.

Very truly yours,

Virage Logic Corporation \s\J. Daniel McCranie J. Daniel McCranie Executive Chairman

ABOUT VIRAGE LOGIC

Virage Logic is a leading provider of semiconductor intellectual property (IP) for the design of complex integrated circuits. The company's highly differentiated product portfolio includes embedded SRAMs, embedded NVMs, embedded test and repair, logic libraries, memory development software, and DDR memory controller subsystems. As the industry's trusted semiconductor IP partner, foundries, IDMs and fabless customers rely on Virage Logic to achieve higher performance, lower power, higher density and optimal yield, as well as shorten time-to-market and time-to-volume.

POWER 3 MEDICAL PRODUCTS INCORPORATED (OTCBB: PWRM) "Up 30.77% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/PWRM.php

Power3 Medical Products Inc. is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

PWRM News:

December 2 - Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics

Will offer proteomic tests to identify Alzheimer's and Parkinson's disease

Transgenomic, Inc. (OTCBB: TBIO) and Power3 Medical Products, Inc. (OTCBB: PWRM) announced that Transgenomic has signed a letter of intent to acquire exclusive rights for Power3 Medical's Neurodegenerative Biomarkers, which include NuroPro , a proposed diagnostic for Alzheimer's and Parkinson's disease. Transgenomic plans to offer NuroPro in its CLIA-certified molecular diagnostics laboratory as well as support the tests with development resources.

Power3's technology assigns a probability score that reflects how closely a patient's sample fits a biostatistical model for a neurological disease (NuroPro ), and indicates if the patient should be recommended for further follow-up by the clinician. These technologies would join Transgenomic's robust portfolio of molecular diagnostics including tests for mitochondrial disorders, oncology and hematology, molecular pathology and inherited diseases.

Craig Tuttle, CEO of Transgenomic, said, "Physicians face a common challenge when treating patients with these devastating diseases -- how to diagnose them earlier and more accurately so their patients can receive treatment sooner and receive greater benefit from treatment. In this respect, the proteomic tests for detection of early disease developed by Power3 are very attractive; particularly when combined with our company's demonstrated strength in robust and sensitive genomics tests for detection of increased disease susceptibility. Moreover, as we are already calling on neurologists with our current lab sales organization, these new assays will add significant depth to our neurological sales portfolio."

Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc., said, "It is critical to have the ability to diagnose Alzheimer's disease more accurately, earlier, and faster than currently available. If physicians can intervene earlier, before the patients suffer debilitation and irreversible damage, the drugs currently used to slow disease progression can be more effective. In addition, the ability to detect Alzheimer's disease processes early and monitor disease progression in the patients' blood will ultimately lead to more effective and personalized treatments."

Helen R. Park, Power3's CEO, said, "This potential agreement will propel the NuroPro diagnostic test to the next level affording the ability to commercialize a physician sought after test for Alzheimer's and Parkinson's Diseases. It is a win/win for both companies."

A final agreement is subject to due diligence investigation and negotiation of a definitive exclusive license and/or acquisition agreement and approval by the Boards of Directors of both companies.

ABOUT NUROPRO

NuroPro is a test designed to diagnose Alzheimer's, Parkinson's, and Lou Gehrig's disease (ALS) in individuals. The test is based on proteomic technology, in which a blood serum sample is drawn from a patient, and the concentration of selected biomarkers residing in a panel of 59 blood serum protein biomarkers of neurodegenerative disease is monitored and the test determines if a patient has a Neurodegenerative disease, such as Alzheimer's, Parkinson's or Lou Gehrig's Disease (ALS).

ABOUT TRANSGENOMIC

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE DHPLC Systems, related consumables and assay kits, Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients.

GLU MOBILE INCORPORATED (NASDAQ: GLUU) "Up 29.17% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GLUU.php

Glu (Nasdaq: GLUU) is a leading global publisher of mobile games. Its portfolio of top-rated games includes original titles Super K.O. Boxing!, Stranded and Brain Genius, and titles based on major brands from partners including Atari, Activision, Konami, Harrah's, Hasbro, Warner Bros., Microsoft, PlayFirst, PopCap Games, SEGA and Sony. Founded in 2001, Glu is based in San Mateo, Calif. and has offices in London, France, Germany, Spain, Italy, Sweden, Poland, Russia, China, Brazil, Chile, Canada and Mexico.

GLUU News:

December 3 - Glu to Develop and Publish Mobile Game Based on Highly-Anticipated Film Watchmen

Glu Mobile Inc. (Nasdaq: GLUU), a leading global publisher of mobile games, today announced that it will be publishing a mobile game based on the forthcoming Warner Bros. Pictures super hero film Watchmen. The game will launch worldwide in conjunction with the film's U.S. premiere in March 2009. Watchmen, based on the most celebrated graphic novel of all-time published by DC Comics, is a thrilling mystery-adventure set in an alternate 1985 America where heroes roam as members of society.

"We are excited to continue our relationship with Warner Bros. to create the mobile game based on this highly anticipated film," said Jill Braff, senior vice president of global publishing, Glu Mobile. "Like the film, the mobile game will engage long-time fans of the novel, as well as those who are getting to know Watchmen for the first time."

Today's announcement marks the fifth title Glu will develop and publish through its licensing agreement with Warner Bros. Digital Distribution. Other titles developed with WBDD include Speed Racer, The Dark Knight, Superman/Batman: Heroes United and Bugs Bunny: Rabbit Rescue.

Watchmen is known for its unconventional take on the lives of super heroes, depicting them as real people, confronting the trials and tribulations of everyday human life. The film is being directed by Zack Snyder who was behind the success of the box office hit 300. The cast includes such stars as Billy Crudup as Dr. Manhattan, Jeffrey Dean Morgan as The Comedian and Matthew Goode in the role of Ozymandias. Other Watchmen are played by Malin Ackerman, Carla Gugino, Jackie Earle Haley and Patrick Wilson.

Watchmen: The Mobile Game will be supported by a suite of personalization content which will be available to consumers in early 2009. For more information, visit www.glu.com.

ABOUT DC COMICS

DC Comics, a Warner Bros. Entertainment Company, is the largest English-language publisher of comics in the world and home to such iconic characters as Superman, Batman, Wonder Woman and the Sandman. These DC Super Heroes and others have starred in comic books, movies, television series (both animated and live-action) and cyberspace, thrilling audiences of all ages for generations.

ASCENT SOLAR TECHNOLOGIES INCORPORATED (NASDAQ: ASTI) "Up 20.50% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ASTI.php

Ascent Solar Technologies, Inc. is a developer of thin-film photovoltaic modules with substrate materials that can be more flexible and affordable than most traditional solar panels. Ascent Solar modules can be directly integrated into standard building materials, space applications, consumer electronics for portable power or configured as stand alone modules for large scale terrestrial deployment. Ascent Solar is located in Littleton, Colorado.

ASTI News:

December 2 - Ascent Solar Achieves Significant Efficiency Milestone

Ascent Solar Technologies, Inc. (Nasdaq: ASTI), a developer of state of the art flexible thin-film solar modules, today announced that it has achieved greater than 9.5% efficiency for its flexible Copper, Indium, Gallium, Selenide (CIGS) monolithically integrated modules.

The U.S. Department of Energy's National Renewable Energy Laboratory (NREL) has independently verified that the modules measured as high as 9.64% in conversion efficiency. The modules tested at NREL were produced from the company's 1.5MW pilot production line.

"We have been working to achieve these efficiencies during our internal optimization process, and we view this achievement as a tremendous breakthrough. The test modules measure six inches wide by one foot long and serves as our building block for portable power and building integrated photovoltaic (BIPV) products," said Dr. Prem Nath, Sr. Vice President of Manufacturing for Ascent Solar. "Our goal continues to be the commercialization of flexible thin-film CIGS modules using a plastic substrate, which we hope will uniquely position Ascent Solar to provide light weight flexible photovoltaic material at low cost."

Lawrence Kazmerksi, Executive Director at NREL, said, "This is significant. Many doubted that a thin-film CIGS solar cell-on-plastic technology could be possible. Ascent Solar not only achieved this, but they now have confirmed efficiencies at NREL on fully integrated, monolithic prototype modules near 10%. This appears to be a substantial leap toward realizing high-performance, inexpensive thin-film solar photovoltaics."

ABOUT NATIONAL RENEWABLE ENERGY LABORATORY

The National Renewable Energy Laboratory (NREL) is the nation's primary laboratory for renewable energy and energy efficiency research and development.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated sixty million free trading shares from a third party for SMAS advertising and promotional activities. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

The Company continues to see advancements with product development and strategic partners, and anticipates additional strategic relationships going forward. The Company intends to display developmental modules this week at SolarPower International 2008 in San Diego, California, at exhibitor booth 729.

"We are very pleased with the manufacturing progress made to-date as we continue on our path toward commercialization. We continue to believe that the market for flexible renewable solar photovoltaics will grow steadily and that Ascent Solar is well positioned to assume a leading role in this burgeoning new market," said Dr. Mohan Misra, Ascent Solar's Chairman and CEO.

About Ascent Solar Technologies:

Ascent Solar Technologies, Inc. is a developer of thin-film photovoltaic modules with substrate materials that can be more flexible and affordable than most traditional solar panels. Ascent Solar modules are designed to be directly integrated into standard building materials, space applications, consumer electronics for portable power or configured as stand alone modules for large scale terrestrial deployment. Ascent Solar is located in Littleton, Colorado.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE: Ascent Solar Technologies, Inc.

For Ascent Solar Technologies, Inc. 
Brian Blackman, 832-515-0928 (Investor Relations) 
bblackman@ascentsolar.com 
or 
Brand Fortified Public Relations 
Kelly Brandner, 303-289-4303 (Media) 
kellybrandner@msn.com

Ascent Solar Technologies, Inc. is a developer of thin-film photovoltaic modules with substrate materials that can be more flexible and affordable than most traditional solar panels. Ascent Solar modules can be directly integrated into standard building materials, space applications, consumer electronics for portable power or configured as stand alone modules for large scale terrestrial deployment. The Company has begun the development of the key production tools that will support its planned 30 MW scale production line which is scheduled for completion in 2009. Ascent Solar is located in Littleton, Colorado.

Ascent Solar encourages strategic relationships that are well positioned to integrate our materials into systems solutions. We envision that these systems will utilize our flexible, lightweight material and unique "plug-and-play" features that should eliminate a significant portion of the wires, cables, connectors, junction boxes and conduit required in current systems.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE: Ascent Solar Technologies, Inc.

Ascent Solar Technologies, Inc. 
Investor Relations 
Brian Blackman, 832-515-0928 
bblackman@ascentsolar.com 
or 
Brand Fortified Public Relations 
Media 
Kelly Brandner, 303-289-4303 
kellybrandner@msn.com